Virios therapeutics, inc. announces closing of public offering

Atlanta--(business wire)---- $viri #biotech--virios therapeutics, inc. (nasdaq: viri), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today the closing of its previously announced underwritten public offering of 10.0 million shares of its common stock at a public offering price of $0.50 per share, for gross proceeds of $5.0 million, before deducting underwriting discounts, commissions a
VIRI Ratings Summary
VIRI Quant Ranking